31.01.2013 • News

Dow Chemical Q4 Profit Misses View

Dow Chemical posted lower-than-expected adjusted profit on Thursday, as demand withered for polyurethane and chlorine around the world, especially in China and Europe.

For the fourth quarter, the net loss widened to $716 million, or 61 cents per share, from $20 million, or 2 cents per share, in the year-earlier quarter.

Excluding one-time items, the company earned 33 cents during the quarter. By that measure, analysts expected 34 cents per share, according to Thomson Reuters I/B/E/S.

Sales fell 1% to $13.92 billion. Analysts looked for sales of $13.69 billion.

Repairs and shutdowns to facilities that make chlorine dented sales of the crucial chemical. Dow Chemical is the world's largest chlorine producer.

Results were especially weak for polyurethane foams, coatings and paints, and electronic materials.

The sharpest drop in volume, the physical amount of product sold, came in Europe, draining overall results.

"Weak volumes in Europe definitely held them back," Deutsche Bank analyst David Begleiter said of Dow Chemical's results.

China also proved a weak spot. "The second half of 2012 saw significant deterioration in the markets we serve, particularly in China," Dow Chemical Chief Executive Andrew Liveris said in a statement.

In an interview on the CNBC cable news channel on Thursday morning, Liveris said he expects sales in China to improve in 2013.

Last fall, the company said it was worried more about deteriorating sales in China than the U.S. fiscal crisis.

Dow Chemical took a $990 million charge in the quarter, part of a plan announced in October to lay off 5% of its workforce, close 20 plants and write down the value of its underperforming lithium ion battery business.

 

Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.